Fig. 4.

-1 and Fig. 4–2 Crude (4–1) and adjusted (4–2) accumulative Survival Function for mortality hazard risk at the end of TB treatment (6 months), post-treatment year 1 (12 M), post-treatment year 2 (24 M), post-treatment year 3 (36 M), post-treatment year 4 (48 M), and post-treatment year 5 (60 M) among HIV/MTB coinfection patients treated with tuberculosis cure (TBC) (n = 680), tuberculosis complete regimen (TBCR) (n = 1289), and tuberculosis treatment failure, patients missing, adverse events (TBFMA) (n = 382) in Southern China. Fig. 4–3 and Fig. 4–4 Adjusted accumulative Survival Function for mortality hazard risk at the end of TB treatment (6 months), post-treatment year 1 (12 M), post-treatment year 2 (24 M), post-treatment year 3 (36 M), post-treatment year 4 (48 M), and post-treatment year 5 (60 M) between stratifications of antiretroviral therapy (n = 362) and of antiretroviral therapy naïve (255) HIV/MTB coinfection patients treated with tuberculosis cure (TBC) (n = 680), tuberculosis complete regimen (TBCR) (n = 1289), and tuberculosis treatment failure, patients missing, adverse events (TBFMA) (n = 382) in Southern China